Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.
Harold J BursteinAngela M DeMicheleMark R SomerfieldNorah L Henrynull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. See the Appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only) .
Keyphrases
- epidermal growth factor receptor
- healthcare
- metastatic breast cancer
- health information
- clinical practice
- primary care
- loop mediated isothermal amplification
- mental health
- endothelial cells
- tyrosine kinase
- public health
- social media
- advanced non small cell lung cancer
- big data
- quality improvement
- deep learning
- risk assessment
- health promotion
- electronic health record
- estrogen receptor
- artificial intelligence